Ravulizumab for treating paroxysmal nocturnal haemoglobinuria [ID1457]
In development [GID-HST10023] Expected publication date: TBC
Search results
496 results
-
-
Lysosomal acid lipase deficiency - sebelipase alfa [ID737]
In development [GID-LYSOSOMALACIDLIPASEDEFICIENCYSEBELIPASEALFAID737] Expected publication date: TBC
-
Afamelanotide for treating erythropoietic protoporphyria [ID927]
In development [GID-HST10009] Expected publication date: TBC
-
Onasemnogene abeparvovec for treating spinal muscular atrophy type 1 [ID1473]
In development [GID-HST10026] Expected publication date: TBC
-
A4250 for treating progressive familial intrahepatic cholestasis [ID1570]
In development [GID-HST10031] Expected publication date: TBC
-
Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]
In development [GID-HST10032] Expected publication date: TBC
-
Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]
In development [GID-HST10033] Expected publication date: TBC
-
Metreleptin for treating lipodystrophy (ID861)
In development [GID-HST10011] Expected publication date: TBC
-
OTL-200 for treating metachromatic leukodystrophy [ID1666]
In development [GID-HST10028] Expected publication date: TBC
-
Avalglucosidase alfa for treating late-onset glycogen storage disease type II [ID3737]
In development [GID-HST10030] Expected publication date: TBC
-
Givosiran for treating acute hepatic porphyria [ID1549]
In development [GID-HST10035] Expected publication date: TBC
-
Setmelanotide for treating obesity caused by LEPR or POMC deficiency [ID3764]
In development [GID-HST10034] Expected publication date: TBC
-
Volanesorsen for treating familial chylomicronaemia syndrome [ID1326]
In development [GID-HST10015] Expected publication date: TBC
-
Human alpha1-proteinase inhibitor for treating emphysema ID856
In development [GID-HST10017] Expected publication date: TBC
-
Velmanase alfa for treating alpha-mannosidosis [ID800]
In development [GID-HST10010] Expected publication date: TBC
-
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [ID1477]
In development [GID-TA10448] Expected publication date: 05 August 2020
-
Elotuzumab for multiple myeloma [ID966]
In development [GID-TA10134] Expected publication date: TBC
-
Caplacizumab for treating adults experiencing an episode of acquired thrombotic thrombocytopenic purpura [ID1185]
In development [GID-TA10361] Expected publication date: TBC
-
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for moderate rheumatoid arthritis after conventional DMARDs only have failed (partial review of TA375) [ID2710]
In development [GID-TA10586] Expected publication date: TBC
-
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (review of HST3) ID1642
In development [GID-TA10642] Expected publication date: TBC
-
Fenfluramine for treating Dravet syndrome [ID1109]
In development [GID-TA10373] Expected publication date: TBC
-
Lung cancer (non-small-cell, EGFR and T790M positive, metastatic) - osimertinib (CDF Review of TA416) [ID1577]
In development [GID-TA10475] Expected publication date: TBC
-
Short bowel syndrome - teduglutide [ID885]
In development [GID-TA10048] Expected publication date: TBC
-
Carfilzomib with dexamethasone and lenalidomide for treating multiple myeloma after at least 1 previous therapy [ID1493]
In development [GID-TA10510] Expected publication date: TBC
-
Mogamulizumab for treated mycosis fungoides or Sézary syndrome cutaneous T-cell lymphoma [ID1405]
In development [GID-TA10305] Expected publication date: 16 September 2020
-
Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529]
In development [GID-TA10522] Expected publication date: TBC
-
Moxetumomab pasudotox for treating hairy-cell leukaemia [ID1142]
In development [GID-TA10288] Expected publication date: 22 September 2021
-
Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]
In development [GID-TA10457] Expected publication date: TBC
-
Solriamfetol for treating excessive waketime sleepiness caused by narcolepsy [ID1602]
In development [GID-TA10524] Expected publication date: TBC
-
Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]
In development [GID-TA10458] Expected publication date: TBC
-
Galcanezumab for preventing migraine [ID1372]
In development [GID-TA10454] Expected publication date: TBC
-
Belimumab for treating active autoantibody-positive systemic lupus erythematosus [ID1591]
In development [GID-TA10626] Expected publication date: 24 March 2021
-
Non-bisphosphonates for treating osteoporosis [ID901]
In development [GID-TA10072] Expected publication date: TBC
-
Nivolumab for previously treated squamous non-small-cell lung cancer (CDF Review TA483) [ID1559]
In development [GID-TA10516] Expected publication date: TBC
-
Nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer (CDF review TA484) [ID1572]
In development [GID-TA10513] Expected publication date: TBC
-
Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (CDF Review TA490) ID1585
In development [GID-TA10538] Expected publication date: TBC
-
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (CDF Review TA600) ID1683
In development [GID-TA10537] Expected publication date: 12 August 2020
-
Avelumab for treating metastatic Merkel cell carcinoma (CDF Review of TA517) ID1617
In development [GID-TA10545] Expected publication date: TBC
-
Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated non-small-cell lung cancer (CDF Review of TA557) [ID1584]
In development [GID-TA10529] Expected publication date: TBC
-
Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure [ID3754]
In development [GID-TA10621] Expected publication date: TBC
-
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy [ID1536]
In development [GID-TA10466] Expected publication date: TBC
-
Budesonide for treating active eosinophilic oesophagitis [ID1202]
In development [GID-TA10372] Expected publication date: TBC
-
Anakinra for treating active Stills disease [ID1463]
In development [GID-TA10392] Expected publication date: TBC
-
TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices [ID1440]
In development [GID-TA10370] Expected publication date: TBC
-
Naldemedine for treating opioid-induced constipation [ID1189]
In development [GID-TA10291] Expected publication date: TBC
-
Liraglutide for managing overweight and obesity [ID740]
In development [GID-TA10388] Expected publication date: TBC
-
Upadacitinib for treating moderate to severe rheumatoid arthritis [ID1400]
In development [GID-TA10389] Expected publication date: TBC
-
Esketamine for treatment-resistant depression (ID1414)
In development [GID-TA10371] Expected publication date: TBC
-
Dupilumab for treating severe asthma [ID1213]
In development [GID-TA10276] Expected publication date: TBC
-
Bempedoic acid for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1515]
In development [GID-TA10534] Expected publication date: TBC